Company Profile
Denali Therapeutics Stock Price, News & Analysis
- Ticker:
- DNLI
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States
Stock performance
23.57 USD (+1.99%)
Close
Last updated: July 27, 2026
3.07B USD
Market cap
Why the stock is moving
The latest monitored company update is “Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026.” The corresponding closing-price reaction is not yet available.
Company overview
Business overview
Denali Therapeutics is a neuroscience company focused on neurodegenerative disease and blood-brain-barrier delivery technology.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Denali sits in CNS biotechnology.
Business Model Characteristics
Its model is built around platform science, partnerships, and the possibility of delivering therapies into the brain more effectively.
Position Within the Biotechnology Landscape
Denali is a platform CNS biotech with meaningful optionality, but the stock still depends on clinical and translational validation.
Future catalysts
Denali's catalysts are DNL310 in Hunter syndrome and the rest of its lysosomal / LRRK2 pipeline, where each update helps decide how strong the neurodegeneration platform really is. The company still needs clean human data to keep the story moving.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
- 02
ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call
ICUI · Source: ICU Medical
- 03
Encompass Health increases and declares dividend on common stock
EHC · Source: Encompass Health Corporation
- 04
Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
TCMD · Source: Tactile Systems Technology, Inc.
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Denali Therapeutics (DNLI)?
Denali Therapeutics (DNLI) most recently closed at 23.57 USD, a +1.99% move versus the previous session.
What is the market cap of Denali Therapeutics (DNLI)?
Denali Therapeutics currently has a market capitalization of 3.07B USD on BioPharmSignal.
What does Denali Therapeutics do?
Denali Therapeutics is a neuroscience company focused on neurodegenerative disease and blood-brain-barrier delivery technology.
On which exchange is DNLI stock listed?
Denali Therapeutics (DNLI) is associated with NASDAQ, United States, MedTech.
What is Denali?
Denali's catalysts are DNL310 in Hunter syndrome and the rest of its lysosomal / LRRK2 pipeline, where each update helps decide how strong the neurodegeneration platform really is.
Which conditions is Denali Therapeutics targeting with Denali?
Denali Therapeutics is associated with neuroscience based on its company overview and current catalyst commentary.
How does Denali Therapeutics describe recent progress with Denali?
Denali's catalysts are DNL310 in Hunter syndrome and the rest of its lysosomal / LRRK2 pipeline, where each update helps decide how strong the neurodegeneration platform really is.
What is Therapeutics?
Denali Therapeutics is a neuroscience company focused on neurodegenerative disease and blood-brain-barrier delivery technology.